#USA #San Francisco #FDA #Aardvark Therapeutics #ARD-101

Aardvark Therapeutics Plunges Again Amid FDA Investigations

Aardvark Therapeutics (NASDAQ: AARD) has faced another turbulent wave, as their stock price plummeted by 32% on May 15, 2026. This significant drop came in the aftermath of the FDA's announcement of a clinical hold on the company's leading drug candidate, ARD-101, which is designed for treating Prader-Willi Syndrome (PWS).

In a surprising twist, this market reaction follows a previous decline on March 2, 2026, when Aardvark disclosed the cessation of its Phase 3 Hunger Elimination of Reduction Objective (HERO) trial. The trial aimed to determine the safety and efficacy of ARD-101 for hyperphagia, a condition characterized by insatiable hunger commonly associated with PWS. In that instance, the shares nosedived by 56%, further revealing investors’ growing unease about the company's future prospects.

Hagens Berman, a national shareholder rights firm, is currently investigating whether Aardvark may have misled its investors regarding the safety and efficacy data of ARD-101 as well as its communications with the FDA. The firm is encouraging affected investors to share their experience and consider participating in the investigation.

The unsettling developments raise concerns about Aardvark's transparency. The May 14 announcement indicating the FDA's clinical hold directly contradicts earlier reassurances from the company. Aardvark previously described ARD-101 as a “first-in-class” drug and assured investors of its tolerable safety profile. They claimed FDA alignment allowed the drug to be administered to patients starting at the age of four, which now appears highly questionable.

According to Aardvark’s announcement, the FDA’s hold applies not just to the HERO trial but to all ongoing studies under their investigational new drug (IND) application for ARD-101. This hold was prompted by serious safety concerns including “reversible cardiac observations” that were noted during preliminary evaluations.

The reaction from investors has been swift and sharp, resulting in a staggering loss of more than 63% in the stock price from its previous month-high, echoing the fears about the viability of ARD-101's development moving forward.

Reed Kathrein, partner at Hagens Berman, has emphasized that they are probing whether Aardvark misinformed investors about the drug's status, creating an atmosphere of uncertainty surrounding its potential market entry. The firm urges anyone with non-public insights into Aardvark's operations to step forward and assist in the investigation.

Potential whistleblowers have the opportunity to gain rewards under the new SEC Whistleblower program, making it an essential moment for individuals knowledgeable about Aardvark’s undertakings to consider their reports seriously.

In conclusion, as the scrutiny continues surrounding Aardvark Therapeutics, the firm’s future remains precarious. While the drug ARD-101 promised a breakthrough in treating PWS, the recent events have cast significant doubt on its development trajectory, leaving investors and stakeholders eager for clarity. As the investigation unfolds, investors will be keenly watching for further announcements that could reveal insight into Aardvark’s strategy moving forward amidst these troubling times.